Oregon Health & Science University (OHSU) is a public research university focusing primarily on health sciences with a main campus, including two hospitals, in Portland, Oregon. The institution was founded in 1887 as the University of Oregon Medical Department and later became the University of Oregon Medical School. In 1974, the campus became an independent, self-governed institution called the University of Oregon Health Sciences Center, combining state dentistry, medicine, nursing, and public health programs into a single center. It was renamed Oregon Health Sciences University in 1981 and took its current name in 2001, as part of a merger with the Oregon Graduate Institute (OGI), in Hillsboro. The university has several partnership programs including a joint PharmD Pharmacy program with Oregon State University in Corvallis.

The university's programs are highly ranked nationally, with the School of Medicine ranking in the top 5 for primary care and family medicine residency ranking #1 by U.S. News & World Report, as well as the ophthalmology residency under Casey Eye Institute ranking in the top 10 by Ophthalmology Times in 2020. It is designated as a "Special Focus - Research Institution" according to the Carnegie Classification.

OHSU encompasses the Jungers Center for Neuroscience Research. The Center is housed on the 4th floor of the Lamfrom Biomedical Research Building, and is dedicated to accelerating the pace at which promising discoveries move from the laboratory to the patient’s bedside.

OHSU also incorporates the Vollum Institute. There are currently 23 faculty scientists, 180 research staffs, postdoctoral fellows and graduate students at the Vollum Institute. The scientists of the institute are doing basic science research on chemicals; glutamate, dopamine mediate neuronal communication, studying how brain function is disrupted in diseases like epilepsy, sound is produced in electrical signals in hearing pathways, proteins signal govern cell death development, and the reason why the synaptic connections between neurons grows stronger or weaker.

Biostax Corp. (formerly known as Immune Therapeutics Inc.) is the developer of Lodonol®, which is the FDA approved Naltrexone in a low dose which acts as an immune systems regulator.

As Immgenuity's IMTV014 moves forward, adding Lodonol® to the regime may enahance the effects of our vaccine. Immgenuity and Biostax plan to collaborate on research involving use of both products separately and together to determine efficacy and tolerability.

Biostax Corp. is a pioneering pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a well-defined path to market. By utilizing a biotech portfolio hub-and-spoke engine, the company plans to advance focused and efficient small-scale biotechnology and pharmaceutical programs through subsidiaries, investment vehicles, or partnerships, and deploy its products from those programs in markets both in the U.S. and internationally for initial commercialization.